Adipotide (FTPP)
Targeted proapoptotic compound
Overview
Adipotide — also called FTPP, short for Phe-Arg-Phe-Phe-Ala-Arg-Lys-Leu-Ala-Lys-Leu-Ala-Lys-Lys-Ala-Leu-Ala-Lys-Leu-Ala-Lys-Ala-Ala-Lys-Lys — is a synthetic proapoptotic peptide designed to do something no other weight loss compound attempts: destroy the blood vessels that feed fat tissue, causing adipose deposits to literally starve and shrink. That's not a metaphor. The mechanism is vascular ablation targeted specifically at white adipose tissue.
The research behind it produced genuinely striking results in obese rhesus monkeys — animals whose metabolic physiology is close enough to humans that the data got real attention. But Adipotide has never been tested in a human clinical trial, and the reason is kidney toxicity. The same aggressive mechanism that kills fat-feeding blood vessels also causes measurable kidney damage in primates. That's where the story currently stalls.
If you're reading this because you've seen Adipotide marketed online or discussed in peptide communities, here's what you need to know: the compound exists, the early animal data is real, and the kidney risk is also real. This page covers all of it.
Mechanism of Action
Prohibitin receptor binding → mitochondrial disruption → apoptosis in adipose vasculature
Most weight loss compounds work through appetite. GLP-1 receptor agonists like semaglutide slow gastric emptying and signal satiety to the brain. Adipotide ignores all of that. It goes after the fat tissue itself — specifically, the blood vessels supplying it.
Here's the mechanism. White adipose tissue (body fat) depends on a network of small blood vessels to stay alive. The endothelial cells lining those vessels express a protein called prohibitin on their surface. Prohibitin is expressed at much higher levels in fat-feeding vasculature than in most other tissues, which is what makes it a viable target.[1]
Adipotide is a chimeric peptide — meaning it's engineered from two functional domains joined together. One domain homes in on the prohibitin receptor and binds to it. The other domain, once inside the cell, disrupts the mitochondrial membrane.[1] When mitochondria lose membrane integrity, the cell can't maintain energy production, and it triggers apoptosis — an orderly, programmed self-destruction sequence.
The result: the blood vessels feeding fat tissue collapse. Without vascular supply, the fat cells themselves undergo apoptosis and are reabsorbed. The fat doesn't get mobilized and burned in the usual metabolic sense — it dies and is cleared. That's a fundamentally different process from what caloric restriction, exercise, or any approved pharmacotherapy does.
Why does this matter mechanistically? Because it means Adipotide could theoretically work independently of appetite, insulin sensitivity, or metabolic rate. You don't need the patient to feel less hungry. You're directly dismantling the infrastructure that keeps fat tissue alive. That's the concept that made the early primate data so interesting — and it's also why the kidney toxicity issue is so consequential. A mechanism this aggressive doesn't stay perfectly contained.
What the Evidence Shows
The most important published study is a 2011 paper by Kolonin et al. in Science Translational Medicine, which tested Adipotide in obese rhesus monkeys.[1] These weren't mildly overweight animals — they were diet-induced obese primates with metabolic profiles resembling human obesity.
Over 28 days of subcutaneous administration at approximately 0.5 mg/kg, the treated monkeys lost roughly 11% of total body weight and showed approximately 27% reduction in BMI (body mass index — the ratio of weight to height squared).[1] Visceral fat — the metabolically dangerous fat stored around internal organs — was disproportionately reduced. MRI imaging confirmed the fat loss was real and substantial. That's a big number for 28 days in a primate model.
The monkeys also showed improvements in insulin sensitivity, which makes sense: visceral fat is a major driver of insulin resistance, so reducing it tends to improve glucose metabolism downstream.[1]
In obese rhesus monkeys treated with Adipotide for 28 days, researchers observed approximately 11% body weight loss, ~27% BMI reduction, and significant visceral fat reduction confirmed by MRI imaging. Insulin sensitivity improved alongside fat loss. These results were published in Science Translational Medicine in 2011.
The kidney findings, however, appeared in the same study. Treated animals showed signs of nephrotoxicity — specifically, elevated markers of kidney stress and structural changes on histological examination.[1] The kidney damage appeared to be dose-dependent, meaning higher doses caused more pronounced effects. Some recovery was observed after treatment stopped, but the signal was clear enough to raise serious concern about translating this to humans.
Side Effects
There are no human clinical trial safety data to report. What follows is based entirely on the primate studies.
What this means practically: Anyone considering this compound — in any context — needs to understand that kidney monitoring would be essential, and that the safety profile in humans is genuinely unknown. The primate nephrotoxicity data isn't a theoretical concern; it's the reason this compound hasn't advanced to human trials.
All side effect information for Adipotide comes from animal studies, primarily obese rhesus monkeys. Human clinical trial safety data has not been published. The kidney toxicity observed in primates is the primary reason human trials have not advanced. Do not interpret animal study findings as a human safety profile.